Sort   by:  
 Page size 
UnknownPrognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Not available
S-EPMC8945292 | biostudies-literature
UnknownThe lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Not available
S-EPMC4741628 | biostudies-literature
UnknownDifferent methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Not available
S-EPMC7809812 | biostudies-literature
UnknownThe expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Not available
S-EPMC4635188 | biostudies-literature
UnknownDiverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Not available
S-EPMC11724937 | biostudies-literature
UnknownSurvival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
Not available
S-EPMC10162955 | biostudies-literature
UnknownEuropean LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Not available
S-EPMC8864653 | biostudies-literature
UnknownBusulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
Not available
S-EPMC2966914 | biostudies-literature
Sort   by:  
 Page size